TargetMol

CGP-59326

Product Code:
 
TAR-T30849
Product Group:
 
Inhibitors and Activators
Supplier:
 
TargetMol
Regulatory Status:
 
RUO
Shipping:
 
cool pack
Storage:
 
-20℃
1 / 1
❮❯

No additional charges, what you see is what you pay! *

CodeSizePrice
TAR-T30849-5mg5mg£850.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30849-50mg50mg£1,661.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T30849-100mg100mg£2,079.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT
How to order with us   Contact us
Stay in control of your spending. These prices have no additional charges, not even shipping!
* Rare exceptions are clearly labelled (only 0.14% of items!).
Multibuy discounts available! Contact us to find what you can save.
This product comes from: United States.
Typical lead time: 10-14 working days.
Contact us for more accurate information.
  • Further Information
  • Documents
  • References
  • Show All

Further Information

Bioactivity:
CGP-59326 is an epidermal growth factor receptor (EGFR) antagonist, which is used in anti-cancer research.
CAS:
173458-56-5
Formula:
C14H13ClN4
Molecular Weight:
272.74
Purity:
0.98
SMILES:
Cc1[nH]c2ncnc(Nc3cccc(Cl)c3)c2c1C

References

1. T?rring N, Dagnaes-Hansen F, S?rensen BS, Nex? E, Hynes NE. ErbB1 and prostate cancer: ErbB1 activity is essential for androgen-induced proliferation and protection from the apoptotic effects of LY294002. Prostate. 2003 Jul 1;56(2):142-9. PubMed PMID: 12746839. 2. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides. Cancer Res. 2002 Jun 1;62(11):3151-8. PubMed PMID: 12036928.